Biomarin Pharmaceutical Inc (BMRN)
91.20
-0.86
(-0.93%)
USD |
NASDAQ |
Apr 24, 16:00
87.90
-3.30
(-3.62%)
After-Hours: 20:00
Biomarin Pharmaceutical Cash from Operations (TTM): 159.26M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 159.26M |
September 30, 2023 | 138.56M |
June 30, 2023 | 161.24M |
March 31, 2023 | 147.40M |
December 31, 2022 | 175.90M |
September 30, 2022 | 180.30M |
June 30, 2022 | 119.04M |
March 31, 2022 | 145.59M |
December 31, 2021 | 304.54M |
September 30, 2021 | 279.97M |
June 30, 2021 | 269.12M |
March 31, 2021 | 214.07M |
December 31, 2020 | 85.36M |
September 30, 2020 | 156.09M |
June 30, 2020 | 140.01M |
March 31, 2020 | 87.94M |
December 31, 2019 | 48.26M |
September 30, 2019 | 40.29M |
June 30, 2019 | 17.37M |
March 31, 2019 | 7.849M |
December 31, 2018 | 20.21M |
September 30, 2018 | -14.55M |
June 30, 2018 | -23.46M |
March 31, 2018 | 29.18M |
December 31, 2017 | -8.757M |
Date | Value |
---|---|
September 30, 2017 | -23.58M |
June 30, 2017 | -72.24M |
March 31, 2017 | -136.83M |
December 31, 2016 | -227.84M |
September 30, 2016 | -293.47M |
June 30, 2016 | -285.96M |
March 31, 2016 | -253.14M |
December 31, 2015 | -219.50M |
September 30, 2015 | -177.56M |
June 30, 2015 | -183.27M |
March 31, 2015 | -181.74M |
December 31, 2014 | -70.42M |
September 30, 2014 | -55.51M |
June 30, 2014 | -56.45M |
March 31, 2014 | -51.80M |
December 31, 2013 | -57.34M |
September 30, 2013 | -36.35M |
June 30, 2013 | -12.65M |
March 31, 2013 | -7.249M |
December 31, 2012 | 17.61M |
September 30, 2012 | 5.11M |
June 30, 2012 | -0.243M |
March 31, 2012 | 14.74M |
December 31, 2011 | 18.42M |
September 30, 2011 | 3.146M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
17.37M
Minimum
Jun 2019
304.54M
Maximum
Dec 2021
151.07M
Average
147.40M
Median
Mar 2023
Cash from Operations (TTM) Benchmarks
Eli Lilly and Co | 4.240B |
Merck & Co Inc | 13.01B |
Pfizer Inc | 8.70B |
Bristol-Myers Squibb Co | 13.86B |
Moderna Inc | -3.118B |